HMGCR and cardiovascular disorder: The evidence presented here calls for a cautious approach towards the re-purposing or re-targeting of HMGCR inhibitors and highlights the need for careful consideration of personalized treatment strategies in individuals at risk of both RA and cardiovascular diseases.